Illumina, Inc. (NASDAQ:ILMN) today announced that the Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.

“We’ve significantly expanded our fleet of Genome Analyzers to ramp up our sequencing capabilities in whole genome, whole exome, and whole transcriptome analysis,” said Robert Nicol, director of Sequencing Operations at the Broad Institute. “We are happy with the technology’s accuracy, ease of use and scalability, as well as continued system improvements that have recently enabled us to generate multiple runs with more than 50 gigabases of high quality sequence data.”

“This latest purchase by the Broad Institute is another strong vote of confidence in Illumina’s Genome Analyzer technology and its capacity to evolve to meet the future needs of one of the world’s leading genome centers,” said Matt Posard, vice president of Worldwide Sales at Illumina. “We continue to focus our innovation on simplifying workflow, enhancing scalability and increasing high-quality runs, as the scope of genetic research expands dramatically.”

Designed for facilities of all sizes, the Illumina Genome Analyzer has been adopted across genome centers worldwide, plus individual research labs, core and service facilities, and biotechnology and pharmaceutical companies. The Genome Analyzer offers the highest rate of daily output and the simplest and most user-friendly workflow. The Genome Analyzer also offers the broadest set of supported applications, including whole transcriptome profiling and discovery, epigenetic studies, whole genome resequencing, de novo sequencing, targeted resequencing, ChIP-sequencing, bi-sulfite sequencing (DNA methylation), small RNA, mRNA, tag profiling and metagenomics. For more information about the Genome Analyzer and to read what customers are doing with Illumina's sequencing technology, please visit http://www.illumina.com/sequencing.

In addition, Illumina reaffirms its revenue guidance of a minimum of $165 million for the fourth quarter of 2009.

About Illumina

Illumina (www.illumina.com) is the leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any obligation to and do not intend to update any forward-looking statements after the date of this release.